Coherus BioSciences, Inc. (NASDAQ:CHRS) Given Consensus Recommendation of “Moderate Buy” by Analysts

Coherus BioSciences, Inc. (NASDAQ:CHRS) has received a consensus recommendation of “Moderate Buy” from the six brokerages that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 1 year target price among brokerages that have covered the stock in the last year is $8.83.

CHRS has been the topic of a number of research analyst reports. HC Wainwright restated a “buy” rating and set a $12.00 price target on shares of Coherus BioSciences in a report on Friday, May 24th. Truist Financial cut their target price on shares of Coherus BioSciences from $8.00 to $7.00 and set a “buy” rating on the stock in a research note on Monday, May 13th.

Institutional Trading of Coherus BioSciences

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Virtu Financial LLC acquired a new position in shares of Coherus BioSciences during the first quarter valued at about $94,000. Bayesian Capital Management LP bought a new position in shares of Coherus BioSciences during the first quarter valued at about $56,000. Price T Rowe Associates Inc. MD boosted its holdings in Coherus BioSciences by 32.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 30,851 shares of the biotechnology company’s stock worth $74,000 after purchasing an additional 7,608 shares during the last quarter. EntryPoint Capital LLC purchased a new stake in Coherus BioSciences in the 1st quarter valued at about $100,000. Finally, CM Management LLC increased its stake in Coherus BioSciences by 21.4% in the 1st quarter. CM Management LLC now owns 1,000,000 shares of the biotechnology company’s stock valued at $2,390,000 after buying an additional 176,000 shares during the last quarter. Institutional investors own 72.82% of the company’s stock.

Coherus BioSciences Stock Down 2.4 %

CHRS stock opened at $1.63 on Tuesday. The firm has a market cap of $187.01 million, a price-to-earnings ratio of -2.09 and a beta of 0.66. The company’s fifty day simple moving average is $1.95 and its 200 day simple moving average is $2.27. Coherus BioSciences has a 12-month low of $1.43 and a 12-month high of $5.47.

Coherus BioSciences (NASDAQ:CHRS) last announced its quarterly earnings data on Thursday, May 9th. The biotechnology company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.33). The firm had revenue of $77.06 million during the quarter, compared to the consensus estimate of $102.00 million. During the same quarter last year, the company earned ($0.89) earnings per share. Research analysts expect that Coherus BioSciences will post -1.14 earnings per share for the current year.

About Coherus BioSciences

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.